What Admerus does

Admerus Biosciences Private Limited is a contract research and development organization (CRO) headquartered in Hyderabad, India, that delivers drug development services to the global biopharma industry. The name derives from the pharmacokinetic framework of Absorption, Distribution, Metabolism, Excretion, and the company's stated positioning is as a turnkey drug development partner rather than a single-service vendor.

The company operates three integrated service modules. Bioclinical Research covers Phase I-IV trials and bioequivalence/bioavailability studies across four independent clinics totaling 100 beds, with a dedicated 8-bed ICU and a 7,000-liter walk-in humidity chamber, supported by ICH-GCP-compliant regulatory affairs, medical writing, and clinical data management. Bioanalytical Research runs an LC-MS/MS platform anchored on four Xevo TQ-S Micro mass spectrometers coupled with UPLC H-Class systems, delivering method development, validation, and study sample analysis for small and large molecules under GLP standards. Biostatistics and Pharmacokinetics provides SAS-based statistical analysis, WinNonlin PK modeling, and CDISC-compliant deliverables (SDTM, ADaM, define.xml, XPTs) from protocol design through database lock. Operations are housed in a 100,000 sqft QBD-designed facility on 2 acres in Hyderabad that is approved as a green building by UNDP and holds Brazilian ANVISA certification in addition to GDPR and ICH-GCP compliance.

The business model is fee-for-service professional services priced through engagement-specific quotes, with no published price list and inquiry routing via [email protected] and [email protected]. Go-to-market is event-driven, with active participation in CPHI North America, DCAT Week, CPHI Frankfurt, CPHI Milan, and CPHI Shanghai to access sponsor pipelines in the US, EU, and APAC. Customers are global biopharma sponsors but are not named in the source material. Ownership is founder-led (Abhiram Koppineedi as Founder and Managing Director) with a CEO, Dr. Sailendra Kumar Goswami, whose prior experience founding and scaling Veeda, GVK Biosciences, Zydus Research Centre, and Raptim Research anchors the commercial credibility of the firm.

Name

Admerus

Legal name

Admerus Biosciences Private Limited

Website

https://admerus.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Admerus Biosciences is an India-based, Hyderabad-headquartered contract research organization serving global biopharma sponsors through three integrated modules: bioclinical research (Phase I-IV and BA/BE), bioanalytical LC-MS/MS services, and CDISC-compliant pharmacokinetics and biostatistics.

Ownership category

akta.pro rank

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research Organization (CRO) Services: Fee-for-service revenue from global biopharma sponsors for contract research and development programs across Bioclinical Research (Phase I-IV, BA/BE studies), Bioanalytical Research (LC-MS/MS method development, validation, subject sample analysis), and Pharmacokinetics & Biostatistics (data management, CDISC deliverables, statistical analysis, regulatory writing).
2. Regulatory & Medical Writing Services: Revenue from regulatory affairs support (eCTD, non-clinical and clinical overviews/summaries), medical writing (protocols, CSRs, manuscripts), and clinical data management services for both paper-based and EDC trials.

Pricing tiers

Go-to-market motion1 record

Core offering

Admerus Biosciences is a contract research and development organization (CRO) that delivers a full-service, turnkey drug development solution for the global biopharma industry. Its three integrated service modules span Bioclinical Research (Phase I-IV trials, BA/BE studies, medical writing, clinical data management, regulatory affairs), Bioanalytical Research (LC-MS/MS method development, validation, and study sample analysis), and Biostatistics/Pharmacokinetics (SAS-based statistical analysis, WinNonlin PK modeling, and CDISC-compliant deliverables). Engagements cover pre-clinical through post-marketing phases, delivered from a 100,000 sqft Hyderabad facility under ICH-GCP and GLP standards.

Product overview

Admerus Biosciences is a contract research and development organization (CRO) that delivers a full-service, turnkey drug development solution for the global biopharma industry through three integrated service modules: Bioclinical Research (clinical trials, BA/BE studies, medical writing, clinical data management, and regulatory affairs), Bioanalytical Research (LC-MS/MS-based method development, validation, and study sample analysis), and Biostatistics / Pharmacokinetics (SAS-based statistical analysis, WinNonlin PK modeling, and CDISC-compliant deliverables). Together these three modules cover the entire clinical development lifecycle from pre-clinical analysis through clinical trials and post-marketing services, supported by a centralized Quality Assurance function, a 100,000 sqft facility in Hyderabad, and compliance with ICH-GCP and GLP standards.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioclinical Research Full-service clinical research offering for global biopharma sponsors covering Phase I-IV studies, bio-availability/bio-equivalence (BA/BE) studies, medical writing (regulatory and scientific), clinical data management, and regulatory affairs, conducted in compliance with ICH-GCP and international regulatory standards.
• Bioanalytical Research Bioanalytical laboratory service for global pharma clients providing LC-MS/MS-based method development, method validation, and analysis of study samples, including quantification of endogenous molecules, multi-analytes, and drugs in complex biological matrices under GLP and regulatory guidelines.
• Biostatistics (Pharmacokinetics and Bio-statistics) Biostatistics and pharmacokinetics service delivering sample size estimation, randomization, PK analysis using WinNonlin, statistical analysis using SAS, CDISC-compliant artifacts (SDTM, ADaM, define.xml, XPTs), and Statistical Analysis Plan/report preparation across pre-clinical, clinical, and post-marketing phases.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• ICON plc: Top-five global CRO providing clinical research, bioanalytical, and consulting services. Comparable as a major global incumbent competing for the same Western biopharma sponsor contracts Admerus targets.
• IQVIA: World's largest CRO offering clinical, bioanalytical, and data services across all phases. Comparable as the dominant incumbent in the global CRO market that Admerus competes against for multi-phase, multi-region sponsor contracts.
• Pharmaron: Global CRO/CDMO with strong China/UK/US footprint offering drug discovery, DMPK, bioanalytical, and clinical services. Comparable because Pharmaron competes for the same global biopharma bioanalytical and early-phase work that Admerus targets.
• Charles River Laboratories: Global CRO providing discovery, safety assessment, bioanalytical, and clinical services. Comparable as an established global incumbent with a substantial bioanalytical and early-phase CRO offering that overlaps with Admerus' core services.

Emerging players

• Lambda Therapeutic Research: Indian CRO offering clinical research, BA/BE, bioanalytical, and regulatory services to global pharma. Comparable as a mid-tier Indian CRO operating in the same BA/BE and bioanalytical segments as Admerus, with similar scale and global sponsor focus.
• Raptim Research: Indian CRO focused on clinical research and BA/BE studies. Comparable because Admerus' CEO founded Raptim before starting Admerus, and both target global biopharma sponsors with similar early-phase CRO services from India.

Direct peers

• Syngene International: Indian integrated CRO/CDMO offering discovery, development, and clinical research services globally. Comparable because Syngene competes head-to-head with Admerus in bioanalytical, clinical, and integrated drug-development work for global biopharma from an India cost base, with significantly larger scale.
• Sai Life Sciences: Indian CRO/CDMO providing drug discovery, development, and bioanalytical services to global pharma and biotech. Comparable because Sai Life operates an India-based integrated CRO model targeting Western sponsors across BA/BE, bioanalytical, and clinical phases — directly overlapping with Admerus' service portfolio.
• GVK Biosciences: Indian CRO providing discovery, clinical research, and bioanalytical services to global biopharma. Comparable because Admerus' CEO previously founded GVK Bio, and both target Western biopharma sponsors with integrated drug-development services from an India cost base.
• Veeda Clinical Research: Indian-headquartered full-service CRO offering BA/BE, Phase I-IV, bioanalytical, and clinical research services to global pharma. Highly comparable because Admerus' CEO Dr. Sailendra Kumar Goswami is the founder of Veeda, and both compete in the same BA/BE and clinical segments with similar service menus.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/admerusbio
• LinkedInlinkedin.com/company/admerus

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Admerus